MediWound Ltd. (MDWD) Income Statement Analysis

See more : KEI Industries Limited (KEI.NS) Income Statement Analysis – Financial Results

Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

MediWound Ltd. (MDWD)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.mediwound.com

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	18.69M	26.50M	23.76M	21.76M	31.79M	3.40M	2.50M	1.56M	601.00K	259.00K	0.00	0.00	0.00
Cost of Revenue	15.11M	13.33M	14.99M	14.22M	11.85M	2.09M	1.58M	2.16M	2.52M	2.79M	0.00	0.00	0.00
Gross Profit	3.58M	13.17M	8.77M	7.55M	19.94M	1.31M	918.00K	-600.00K	-1.92M	-2.53M	0.00	0.00	0.00
Gross Profit Ratio	19.15%	49.69%	36.91%	34.67%	62.73%	38.61%	36.78%	-38.51%	-319.13%	-975.29%	0.00%	0.00%	0.00%
Research & Development	7.47M	10.18M	10.26M	7.70M	4.97M	4.07M	5.46M	7.07M	6.02M	5.35M	3.64M	1.56M	3.02M
General & Administrative	8.57M	8.33M	6.11M	8.69M	9.31M	7.99M	9.14M	12.49M	13.29M	4.72M	1.63M	1.14M	1.24M
Selling & Marketing	2.80M	2.04M	3.39M	3.23M	4.06M	4.19M	5.36M	8.40M	9.28M	8.83M	2.26M	0.00	0.00
SG&A	11.38M	10.37M	9.74M	8.69M	9.31M	7.99M	9.14M	12.49M	13.29M	13.55M	3.89M	1.14M	1.24M
Other Expenses	24.00K	958.00K	-710.00K	-144.00K	1.17M	-751.00K	56.00K	66.00K	59.00K	49.00K	57.00K	33.00K	24.00K
Operating Expenses	18.87M	21.51M	19.99M	16.39M	15.45M	5.27M	14.61M	19.56M	19.31M	18.90M	7.58M	2.73M	4.29M
Cost & Expenses	33.98M	34.84M	34.98M	30.60M	27.30M	7.36M	16.18M	21.71M	21.83M	21.69M	7.58M	2.73M	4.29M
Interest Income	2.34M	270.00K	11.00K	297.00K	434.00K	412.00K	0.00	1.27M	288.00K	4.67M	1.00K	6.00K	32.00K
Interest Expense	427.00K	8.92M	903.00K	832.00K	925.00K	892.00K	478.00K	847.00K	444.00K	2.11M	2.44M	673.00K	591.00K
Depreciation & Amortization	1.30M	1.27M	1.24M	1.09M	1.15M	577.00K	567.00K	589.00K	503.00K	492.00K	336.00K	267.00K	196.00K
EBITDA	-4.89M	-18.09M	-11.22M	-7.75M	3.42M	-5.09M	-13.12M	-18.30M	-20.72M	-18.33M	-6.50M	12.25M	-4.10M
EBITDA Ratio	-26.19%	-35.22%	-42.01%	-35.61%	17.75%	-99.47%	-525.64%	-1,255.84%	-3,448.25%	-6,281.85%	0.00%	0.00%	0.00%
Operating Income	-15.29M	-8.35M	-11.22M	-8.84M	4.49M	-3.96M	-13.69M	-20.16M	-21.23M	-21.43M	-7.58M	-2.73M	-4.29M
Operating Income Ratio	-81.83%	-31.50%	-47.22%	-40.62%	14.13%	-116.44%	-548.36%	-1,293.65%	-3,531.95%	-8,272.97%	0.00%	0.00%	0.00%
Total Other Income/Expenses	8.76M	-11.18M	-2.30M	-436.00K	-2.43M	-1.71M	-846.00K	1.27M	-444.00K	2.55M	-920.00K	14.72M	-532.00K
Income Before Tax	-6.53M	-19.52M	-13.52M	-9.28M	2.07M	-5.67M	-14.53M	-18.89M	-21.67M	-18.88M	-8.50M	11.99M	-4.82M
Income Before Tax Ratio	-34.95%	-73.68%	-56.91%	-42.62%	6.50%	-166.57%	-582.25%	-1,212.13%	-3,605.82%	-7,287.64%	0.00%	0.00%	0.00%
Income Tax Expense	185.00K	78.00K	27.00K	325.00K	-1.65M	-9.69M	8.46M	-1.27M	861.00K	-2.55M	7.77M	-13.67M	1.88M
Net Income	-6.72M	-19.60M	-13.55M	-9.60M	3.72M	-1.06M	-22.15M	-18.89M	-22.09M	-18.88M	-15.35M	10.94M	-6.17M
Net Income Ratio	-35.94%	-73.97%	-57.03%	-44.12%	11.70%	-31.08%	-887.38%	-1,212.13%	-3,675.21%	-7,287.64%	0.00%	0.00%	0.00%
EPS	-0.75	-3.93	-3.48	-2.47	0.96	-0.27	-6.64	-6.05	-7.13	-6.65	-5.28	3.76	-2.12
EPS Diluted	-0.75	-3.93	-3.48	-2.47	0.96	-0.27	-6.64	-6.05	-7.13	-6.65	-5.28	3.76	-2.12
Weighted Avg Shares Out	9.01M	4.99M	3.89M	3.89M	3.88M	3.87M	3.33M	3.12M	3.10M	2.84M	2.91M	2.91M	2.91M
Weighted Avg Shares Out (Dil)	9.01M	4.99M	3.89M	3.89M	3.88M	3.87M	3.33M	3.12M	3.10M	2.84M	2.91M	2.91M	2.91M

MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript

November 15, 2022seekingalpha.com

MediWound Ltd. (NASDAQ:MDWD ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference Call Participants Josh Jennings - Cowen Francois Brisebois...

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

November 15, 2022zacks.com

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript

August 10, 2022seekingalpha.com

MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin -...

MediWound Schedules Second Quarter 2022 Financial Results

August 1, 2022globenewswire.com

Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET

MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript

May 17, 2022seekingalpha.com

MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief...

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

May 17, 2022zacks.com

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound Posts Promising EscharEx Data For Chronic Wounds

May 12, 2022benzinga.com

MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). The study met its primary and secondary endpoints and wound closure safety measurements.

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

May 10, 2022globenewswire.com

YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first...